The US Food and Drug Administration has granted breakthrough therapy designation for United Kingdom-based GlaxoSmithKline's meningitis B vaccine, Bexsero [Meningococcal group B Vaccine (rDNA, component, adsorbed)], it was reported yesterday.
The approval is intended for the development of the vaccine in the prevention of Invasive Meningococcal Disease caused by serogroup B in children 2-10 years of age. It is the first vaccine in the world to receive the Breakthrough Therapy Designation twice.
GSK Vaccines chief scientist, Rino Rappuoli, said, 'This designation emphasises the importance of tackling big scientific challenges like meningitis B and breaking new ground in disease prevention through approaches like reverse vaccinology. GSK is committed to the pursuit of innovative vaccines that help protect against serious diseases with significant unmet need.'
Bexsero is licensed in more than 35 countries.
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma